Valneva's Lyme Vaccine Candidate VLA15 Shows Positive Phase 2 Booster Results with Favorable Safety Profile.

Valneva's Lyme disease vaccine candidate VLA15 has shown strong Phase 2 booster results with a favorable safety profile six months after administration. The study demonstrated a strong anamnestic immune response and consistent findings across all age groups, reinforcing the potential benefits of an annual vaccination. The vaccine has advanced the furthest in clinical development, with all vaccinations completed in the pivotal VALOR Phase 3 trial.